Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
CAMBRIDGE, Mass., March 28, 2023 -- Synlogic, Inc. , the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency issued a... | March 28, 2023